Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Kenvue (KVUE) stock in plain English

Free brief · no signupStart here
KVUEPublished Nov 7, 2026
Kenvue Inc
Consumer Defensive · Household & Personal Products
Manufactures and markets personal care, oral care, and over-the-counter wellness products worldwide.
Assets:
Manufacturing footprintOperates approximately 25 internal manufacturing sites worldwide.
Global workforceEmploys around 22,000 full-time team members across regional hubs.
Self-care portfolioControls core over-the-counter lines like Tylenol, Motrin, and Zyrtec.
Locked assetIn the full report
Checked Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

54
OPS ScoreOperating finances
Latest quote
-Quote unavailable
$37.09B
22.0×
$15.52B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 07, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was KVUE. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Kenvue (KVUE) do?

Kenvue Inc (KVUE) is a U.S.-listed company in Consumer Defensive (Household & Personal Products). What it does: Manufactures and markets personal care, oral care, and over-the-counter wellness products worldwide. Operates a global consumer health business spun off from Johnson & Johnson, selling iconic personal care brands. It is worth $37.09B on the market and sold $15.52B over the last year.

Market cap
$37.09B
P/E ratio
22.0×
Annual sales
$15.52B
Sector
Consumer Defensive
Industry
Household & Personal Products
Brief updated
Nov 07, 2026

Brands and businesses behind KVUE

  • Tylenol: Sells acetaminophen pain relief and fever reducing medicines through retail pharmacies and grocery stores.
  • Neutrogena: Offers facial skincare, sun protection, and cosmetic products through mass retailers and online platforms.
  • Listerine: Generates revenue from antiseptic mouthwashes and breath care products sold through supermarkets and drugstores.
  • Aveeno: Produces oat-based body lotions, cleansers, and hair care items sold to global consumers.
  • Band-Aid: Sells adhesive bandages and first aid wound care supplies across supermarkets and pharmacies.
  • Zyrtec: Sells over-the-counter allergy relief medication to retail shoppers and pharmacy customers.

KVUE’s flags, in plain English

Each flag is a number from Kenvue’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.

Wide Gross Margin

Gross margin of 58.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Pays You to Hold

Pays a 4.33% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.

Fat Margins

Profit margin of 10.9%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Runway Is Short

This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about KVUE

How big is Kenvue?

Kenvue’s market cap is $37.09B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $15.52B: what customers paid the company over the last year, before any costs.

What is KVUE’s P/E ratio?

KVUE’s P/E ratio is 22.0×. Investors pay about 22.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with KVUE?

The company carries over seven billion dollars in long-term debt stemming from its spin-off from Johnson & Johnson. That is one risk on Kenvue’s card. Its first risk flag is Runway Is Short, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Kenvue’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KVUE’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card